Evidence map›Paper›PMID 25368575›Full record

ReviewFrontiers in aging neuroscience2014

Nutrition and prevention of Alzheimer's dementia.

Arun Swaminathan, Gregory A Jicha

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05153941 (DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05153941 active not recruitingnot on this mapstarted 2022, after this paper: background citation

DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders (ADRD)

TypeobservationalSponsorAltoidaRan2022 to 2030Enrolled3,500ConditionsAlzheimer's Disease, Mild Cognitive Impairment
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Aging · 2020
    Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Arun SwaminathanDepartment of Neurology and Sanders-Brown Center on Aging, College of Medicine, University of Kentucky Lexington, KY, USA.
Gregory A JichaDepartment of Neurology and Sanders-Brown Center on Aging, College of Medicine, University of Kentucky Lexington, KY, USA.
University of Kentucky · US

Funding

TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI SCHMITT, FREDERICK · 2006 to 2020
$23.3M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
Prevention of Alzheimer's Diseae by Vitamin E and SeleniumR01AG019241 · NIA · UNIVERSITY OF KENTUCKY · PI SCHMITT, FREDERICK · 2001 to 2012
$12.1M
Role of impaired cognitive states & risk factors in conversion to mixed dementiasR01AG038651 · NIA · UNIVERSITY OF KENTUCKY · PI ABNER, ERIN, KRYSCIO, RICHARD J. · 2011 to 2023
$6.1M
Aging of Frontal Structure and Function in Down Syndrome and DementiaR01HD064993 · NICHD · UNIVERSITY OF KENTUCKY · PI HEAD, ELIZABETH, SCHMITT, FREDERICK · 2009 to 2019
$5.1M
Early Detection and Prevention of Mild Cognitive Impairment due to Cerebrovascular DiseaseR01NR014189 · NINR · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, MOSER, DEBRA KAY · 2012 to 2016
$2.0M
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer diseaseR01AG042419 · NIA · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, NELSON, PETER T. · 2013 to 2016
$1.6M
NCATS NIH HHS UL1 TR000117NIA NIH HHS P30 AG028383NIA NIH HHS R01 AG019241NIA NIH HHS R01 AG038651NIA NIH HHS R01 AG042419NIA NIH HHS U01 AG010483NICHD NIH HHS R01 HD064993NINR NIH HHS R01 NR014189
6 · The paper itself

Abstract

A nutritional approach to prevent, slow, or halt the progression of disease is a promising strategy that has been widely investigated. Much epidemiologic data suggests that nutritional intake may influence the development and progression of Alzheimer's dementia (AD). Modifiable, environmental causes of AD include potential metabolic derangements caused by dietary insufficiency and or excess that may be corrected by nutritional supplementation and or dietary modification. Many nutritional supplements contain a myriad of health promoting constituents (anti-oxidants, vitamins, trace minerals, flavonoids, lipids, …etc.) that may have novel mechanisms of action affecting cellular health and regeneration, the aging process itself, or may specifically disrupt pathogenic pathways in the development of AD. Nutritional modifications have the advantage of being cost effective, easy to implement, socially acceptable and generally safe and devoid of significant adverse events in most cases. Many nutritional interventions have been studied and continue to be evaluated in hopes of finding a successful agent, combination of agents, or dietary modifications that can be used for the prevention and or treatment of AD. The current review focuses on several key nutritional compounds and dietary modifications that have been studied in humans, and further discusses the rationale underlying their potential utility for the prevention and treatment of AD.

Indexed as

Alzheimerclinical trialnutritionpreventiontreatment

Identifiers

PMID25368575
PMCPMC4202787
OpenAlexW1977104428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.